Global Orally Disintegrating Tablets Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Orally Disintegrating Tablets Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
Orally Disintegrating Tablets report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Orally Disintegrating Tablets market is projected to reach US$ 30610 million in 2034, increasing from US$ 13890 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2034. Demand from CNS Diseases and Gastrointestinal Diseases are the major drivers for the industry.
Global Orally Disintegrating Tablet main manufactuers include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb and Conquer, totally accounting for about 17% of the market. North America is the largest market of glass packaging, holding a share more than 40%. As for the types of products, it can be divided into anti-psychotics drug, anti-epileptics drug and others. As for the applications of products, it is widely used in CNS diseases, gastrointestinal diseases, CVS diseases and others. The most common application is in CNS diseases packaging, with a share about 55%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orally Disintegrating Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Orally Disintegrating Tablets market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Orally Disintegrating Tablets, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Orally Disintegrating Tablets industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Orally Disintegrating Tablets in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Orally Disintegrating Tablets introduction, etc. Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Orally Disintegrating Tablets market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Orally Disintegrating Tablets report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Orally Disintegrating Tablets market is projected to reach US$ 30610 million in 2034, increasing from US$ 13890 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2034. Demand from CNS Diseases and Gastrointestinal Diseases are the major drivers for the industry.
Global Orally Disintegrating Tablet main manufactuers include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb and Conquer, totally accounting for about 17% of the market. North America is the largest market of glass packaging, holding a share more than 40%. As for the types of products, it can be divided into anti-psychotics drug, anti-epileptics drug and others. As for the applications of products, it is widely used in CNS diseases, gastrointestinal diseases, CVS diseases and others. The most common application is in CNS diseases packaging, with a share about 55%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orally Disintegrating Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Teva
Merck
Mylan
Pfizer
Johnson and Johnson
GSK
Otsuka
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Orally Disintegrating Tablets market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Orally Disintegrating Tablets, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Orally Disintegrating Tablets industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Orally Disintegrating Tablets in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Orally Disintegrating Tablets introduction, etc. Orally Disintegrating Tablets Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Orally Disintegrating Tablets market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices